Advertisement

Topics

Novartis next generation eye drug outperforms Eylea

07:06 EDT 20 Jun 2017 | pharmaphorum

Novartis is to file its next-generation eye drug in 2018 after it won out in a head-to-head trial with Bayer/Regeneron’s rival, Eylea. Brolucizumab (RTH258) could offer a convenience advantage to patients with wet age-related macular dege...

Original Article: Novartis next generation eye drug outperforms Eylea

NEXT ARTICLE

More From BioPortfolio on "Novartis next generation eye drug outperforms Eylea"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...